AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that management will present at the following investor conferences during the month of June:

• June 9, at 8:00 a.m. ET – 9th Annual Needham Healthcare Conference in New York City;
• June 10, at 4:30 p.m. ET – Jefferies 2010 Global Life Sciences Conference in New York City; and
• June 15, at 2:30 p.m. PT – Goldman Sachs 31st Annual Global Healthcare Conference in Los Angeles, CA.

Live webcasts of each presentation will be accessible through the Investors section of the company’s website at www.amagpharma.com. Following each conference, the webcast will be archived on the AMAG Pharmaceuticals, Inc. website for approximately two weeks.

About AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary technology for the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. On June 30, 2009, AMAG received approval from the U.S. Food and Drug Administration to market Feraheme® (ferumoxytol) Injection for intravenous (IV) use for the treatment of iron deficiency anemia in adult chronic kidney disease patients. For additional company and product information, please visit www.amagpharma.com.

Feraheme is a registered trademark of AMAG Pharmaceuticals, Inc.